70 results
8-K
EX-99.1
RYTM
Rhythm Pharmaceuticals Inc.
7 May 24
Rhythm Pharmaceuticals Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
7:10am
months ended March 31, 2023. The year-over-year increase was primarily due to in-process research and development costs totaling $92.4 million … -time costs recorded in the three months ended March 31, 2023, for the purchase of research and development assets from Xinvento, BV.
S,G&A Expenses
8-K
EX-99.1
5buisqrz9r824ww48
22 Feb 24
Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update
7:01am
8-K
EX-99.1
jgh8lr
7 Nov 23
Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
qr8lum6
1 Aug 23
Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business
7:05am
8-K
EX-99.1
94s3wji2
2 May 23
Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update
7:05am
8-K
EX-99.1
p7yekbt0r8 ki3p8
8 Nov 22
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
7:03am
8-K
EX-99.1
prd4j 5kby59
2 Aug 22
Rhythm Pharmaceuticals Reports Second Quarter 2022 Financial Results and Business Update
7:02am
8-K
EX-99.1
0kohaeme
3 May 22
Rhythm Pharmaceuticals Reports First Quarter 2022 Financial Results and Business Update
7:05am